WESTLAKE, Texas--(BUSINESS WIRE)--MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner ...
WESTLAKE, Texas MiddleBrook Pharmaceuticals plans to promote its extended-release antibiotic by expanding a Web-based marketing program, the drug maker announced Wednesday. IncreaseRx is a virtual ...
MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals The FDA has approved Moxatag (amoxicillin extended-release tablets, from MiddleBrook) 775mg for the treatment of patients ≥12 years ...
MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals Moxatag (amoxicillin extended-release) 775mg tablets will be made available by MiddleBrook Pharmaceuticals in the beginning of March ...
LONDON (ShareCast) - (ShareCast News) - Pharmaceutical group Vernalis (Stuttgart: BBP2.SG - news) has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand ...
MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and ...
GERMANTOWN, Md. MiddleBrook Pharmaceuticals has received approval from the Food and Drug Administration for its application for a once daily antibiotic form of amoxicillin extended release tablets, ...
The first and only FDA-approved once-daily amoxicillin will be promoted to health care professionals nationwide WESTLAKE, Texas, Jan. 7 /PRNewswire-FirstCall ...
Vernalis plc ("Vernalis" or the "Company") was informed yesterday that Suir Pharma Limited ("Suir") of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag®, has been placed into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results